• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Application o Market segments o Comparison by Application placement o Neurological disorders - Market size and forecast 2019-2024 o Cancer - Market size and forecast 2019-2024 o Others - Market size and forecast 2019-2024 o Market opportunity by Application • Market Segmentation by Technology o Market segments o Comparison by Technology placement o Antisense/RNAi oligonucleotides - Market size and forecast 2019-2024 o Others - Market size and forecast 2019-2024 o Market opportunity by Technology • Customer landscape o Overview • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o APAC - Market size and forecast 2019-2024 o South America - Market size and forecast 2019-2024 o MEA - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography • Drivers, Challenges, and Trends o Market drivers o Volume driver - Demand led growth o Volume driver - Supply led growth o Volume driver - External factors o Volume driver - Demand shift in adjacent markets o Price driver - Inflation o Price driver - Shift from lower to higher priced units o Market challenges o Market trends • Vendor Landscape o Overview o Landscape disruption • Vendor Analysis o Vendors covered o Market positioning of vendors o Alnylam Pharmaceuticals Inc. o Arrowhead Pharmaceuticals Inc. o Biogen Inc. o Dynavax Technologies Corp. o GlaxoSmithKline Plc o Ionis Pharmaceuticals Inc. o Merck & Co. Inc. o Miragen Therapeutics Inc. o PCI Biotech Holding ASA o Sarepta Therapeutics Inc. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibits • 1.Key Finding 1 • 2.Key Finding 2 • 3.Key Finding 3 • 4.Key Finding 5 • 5.Key Finding 6 • 6.Key Finding 7 • 7.Key Finding 8 • 8.Key Finding 9 • 9.Market in focus • 10.Parent market • 11.Market characteristics • 12.Offerings of vendors included in the market definition • 13.Market segments • 14.Global - Market size and forecast 2019 - 2024 ($ million) • 15.Global market: Year-over-year growth 2019 - 2024 (%) • 16.Five forces analysis 2019 & 2024 • 17.Bargaining power of buyers • 18.Bargaining power of suppliers • 19.Threat of new entrants • 20.Threat of substitutes • 21.Threat of rivalry • 22.Market condition - Five forces 2019 • 23.Application placement - Market share 2019-2024 (%) • 24.Comparison by Application placement • 25.Neurological disorders - Market size and forecast 2019-2024 ($ million) • 26.Neurological disorders - Year-over-year growth 2019-2024 (%) • 27.Cancer - Market size and forecast 2019-2024 ($ million) • 28.Cancer - Year-over-year growth 2019-2024 (%) • 29.Others - Market size and forecast 2019-2024 ($ million) • 30.Others - Year-over-year growth 2019-2024 (%) • 31. Market opportunity by Application • 32.Technology placement - Market share 2019-2024 (%) • 33.Comparison by Technology placement • 34.Antisense/RNAi oligonucleotides - Market size and forecast 2019-2024 ($ million) • 35.Antisense/RNAi oligonucleotides - Year-over-year growth 2019-2024 (%) • 36.Others - Market size and forecast 2019-2024 ($ million) • 37.Others - Year-over-year growth 2019-2024 (%) • 38. Market opportunity by Technology • 39.Customer landscape • 40.Market share by geography 2019-2024 (%) • 41.Geographic comparison • 42.North America - Market size and forecast 2019-2024 ($ million) • 43.North America - Year-over-year growth 2019-2024 (%) • 44.Europe - Market size and forecast 2019-2024 ($ million) • 45.Europe - Year-over-year growth 2019-2024 (%) • 46.APAC - Market size and forecast 2019-2024 ($ million) • 47.APAC - Year-over-year growth 2019-2024 (%) • 48.South America - Market size and forecast 2019-2024 ($ million) • 49.South America - Year-over-year growth 2019-2024 (%) • 50.MEA - Market size and forecast 2019-2024 ($ million) • 51.MEA - Year-over-year growth 2019-2024 (%) • 52.Key leading countries • 53.Market opportunity by geography ($ million) • 54.Impact of drivers and challenges • 55.Vendor landscape • 56.Landscape disruption • 57.Industry risks • 58.Vendors covered • 59.Market positioning of vendors • 60.Alnylam Pharmaceuticals Inc. - Overview • 61.Alnylam Pharmaceuticals Inc. - Business segments • 62.Alnylam Pharmaceuticals Inc. - Key offerings • 63.Alnylam Pharmaceuticals Inc. - Key customers • 64.Alnylam Pharmaceuticals Inc. - Segment focus • 65.Arrowhead Pharmaceuticals Inc. - Overview • 66.Arrowhead Pharmaceuticals Inc. - Business segments • 67.Arrowhead Pharmaceuticals Inc. - Key offerings • 68.Arrowhead Pharmaceuticals Inc. - Key customers • 69.Arrowhead Pharmaceuticals Inc. - Segment focus • 70.Biogen Inc. - Overview • 71.Biogen Inc. - Business segments • 72.Biogen Inc. - Key offerings • 73.Biogen Inc. - Key customers • 74.Biogen Inc. - Segment focus • 75.Dynavax Technologies Corp. - Overview • 76.Dynavax Technologies Corp. - Business segments • 77.Dynavax Technologies Corp. - Key offerings • 78.Dynavax Technologies Corp. - Key customers • 79.Dynavax Technologies Corp. - Segment focus • 80.GlaxoSmithKline Plc - Overview • 81.GlaxoSmithKline Plc - Business segments • 82.GlaxoSmithKline Plc - Key offerings • 83.GlaxoSmithKline Plc - Key customers • 84.GlaxoSmithKline Plc - Segment focus • 85.Ionis Pharmaceuticals Inc. - Overview • 86.Ionis Pharmaceuticals Inc. - Business segments • 87.Ionis Pharmaceuticals Inc. - Key offerings • 88.Ionis Pharmaceuticals Inc. - Key customers • 89.Ionis Pharmaceuticals Inc. - Segment focus • 90.Merck & Co. Inc. - Overview • 91.Merck & Co. Inc. - Business segments • 92.Merck & Co. Inc. - Key offerings • 93.Merck & Co. Inc. - Key customers • 94.Merck & Co. Inc. - Segment focus • 95.Miragen Therapeutics Inc. - Overview • 96.Miragen Therapeutics Inc. - Business segments • 97.Miragen Therapeutics Inc. - Key offerings • 98.Miragen Therapeutics Inc. - Key customers • 99.Miragen Therapeutics Inc. - Segment focus • 100.PCI Biotech Holding ASA - Overview • 101.PCI Biotech Holding ASA - Business segments • 102.PCI Biotech Holding ASA - Key offerings • 103.PCI Biotech Holding ASA - Key customers • 104.PCI Biotech Holding ASA - Segment focus • 105.PCI Biotech Holding ASA - Segment focus • 106.Sarepta Therapeutics Inc. - Overview • 107.Sarepta Therapeutics Inc. - Business segments • 108.Sarepta Therapeutics Inc. - Key offerings • 109.Sarepta Therapeutics Inc. - Key customers • 110.Sarepta Therapeutics Inc. - Segment focus • 111.Currency conversion rates for US$ • 112.Research Methodology • 113.Validation techniques employed for market sizing • 114.Information sources • 115.List of abbreviations

Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Miragen Therapeutics Inc., PCI Biotech Holding ASA, Sarepta Therapeutics Inc.